Walking impairment, fatigue, and spasticity are among the most disabling symptoms in Multiple Sclerosis (MS). While disease-modifying therapies can reduce relapse activity and slow progression, many patients still need effective MS therapy for gait and daily function, especially those with moderate-to-severe disability.

A new Frontiers in Medicine publication (January 2026) adds strong momentum to a growing clinical direction: recoveriX, a brain-computer interface (BCI) rehabilitation for multiple sclerosis. The study reports that a motor-imagery BCI combined with functional electrical stimulation (FES) and virtual reality (VR) implemented with recoveriX was associated with clinically meaningful improvements in walking endurance, mobility, spasticity, and patient-reported outcomes, with benefits maintained for up to 6 months.

Why this is important for MS therapy today

Many rehabilitation approaches rely on repeated movement practice. But in MS, the reality is often different: fatigue limits training intensity, mobility limitations reduce safe gait practice, and therapy time is scarce. That’s why therapies that can deliver high-quality, task-specific input without exhausting the patient are gaining attention.

recoveriX is a BCI rehabilitation for Multiple Sclerosis designed to do exactly that by creating a closed-loop rehabilitation process:

• The patient performs motor imagery (intention to move).
• EEG detects the intended movement pattern.
• The system triggers FES and VR feedback in real-time, only when intention is detected.

This matters clinically because feedback is no longer “always on.” It becomes contingent on the patient’s brain activity supporting more efficient motor relearning.

What the Frontiers in Medicine study found

Clinically meaningful walking improvement (6MWT)

The primary outcome was the 6-Minute Walk Test (6MWT), a cornerstone in MS gait rehabilitation because it reflects real-world walking endurance.

After 30 sessions:

• 6MWT distance increased by +37.3 meters post-treatment
• Improvements were maintained during follow-up, still above baseline at 6 months

The reported gains from recoveriX MS therapy exceeded commonly used thresholds for clinically meaningful change in MS which is an important point for neurologists evaluating whether an intervention is truly functional, not just statistically significant.

Faster mobility and gait speed (TUG, T25FW)

The study also found improvements in:

• Timed Up and Go (TUG): faster mobility and coordination
• Timed 25-Foot Walk (T25FW): improved walking speed post-treatment

For clinicians, these outcomes align with everyday goals: reducing time-to-stand, improving turning stability, and supporting safer ambulation.

Reduced spasticity and better patient-reported outcomes

In addition to objective gait measures, the study reports improvements from recoveriX in:

• Spasticity (Modified Ashworth Scale)
• MSIS-29 (MS impact on daily life)
• MFIS (fatigue impact)

That combination is clinically relevant: improved performance plus improved perceived function and fatigue burden which are key targets in MS therapy and long-term rehabilitation planning.

Safety profile supports broader clinical use

No adverse events were reported during training or assessments, and dropouts were due to logistics rather than safety or fatigue concerns. For hospitals and rehab centers, that’s essential when evaluating new technologies for routine care.

Why hospitals and rehab centers should use recoveriX in acute and subacute care

Most technology-based MS rehab is introduced late, even after months or years of disability. But acute and subacute settings are where structured neurorehabilitation can influence trajectory, especially when patients can’t tolerate high-dose walking practice.

recoveriX supports earlier use because it is:

• Seated and fatigue-sparing
• Task-specific for gait networks (ankle/leg motor imagery + contingent feedback)
• Standardizable (session structure, outcome tracking, repeatable dosing)

For acute and subacute units, this can complement physiotherapy when:

• fatigue limits gait training volume
• spasticity and impaired motor control restrict safe ambulation
• patients need intensive neurorehabilitation but lack functional walking capacity

In practical terms, recoveriX can help rehab teams deliver a measurable “dose” of neurotraining even when traditional gait training is not yet feasible.

Is this a “new MS treatment”?

It’s not a replacement for medical therapy but it is a compelling new MS treatment approach in rehabilitation: using brain-driven, closed-loop training to improve function.

For neurologists, the clinical positioning is clear:

• Adjunct MS therapy for gait impairment, fatigue, and mobility limitations
• Particularly relevant for patients with moderate-to-severe disability who struggle to engage in conventional gait programs
• A structured program that can be integrated into hospital, inpatient, and outpatient pathways

How to implement a recoveriX MS rehab program (clinically)

If your hospital or rehab center is evaluating a program, align implementation with the study structure:

• 30 sessions delivered 2–3x/week
• Track outcomes used in the publication:
  • 6MWT, TUG, T25FW
  • spasticity scoring
  • MSIS-29 and fatigue metrics (MFIS or equivalent)
  • recording of before/after videos

This makes it easier to communicate results internally (quality metrics), clinically (referrer confidence), and externally (patient expectations).

Conclusion: a clinically relevant step forward in MS therapy

This publication supports a meaningful shift in multiple sclerosis rehabilitation: moving from open-loop assistance to closed-loop, brain-driven therapy with measurable, durable outcomes.

For hospitals and rehab centers, the takeaway is practical: recoveriX is not only a research concept—this is a structured intervention with real functional endpoints and follow-up durability, well-suited to acute and subacute neurorehabilitation workflows.